Metronomic capecitabine as second-line treatment for patients with hepatocellular carcinoma with preserved liver function: A phase II study.

被引：1
|
作者：
de Rosa, F.
Agostini, V.
Di Girolamo, S.
Andreone, P.
Trevisani, F.
Bolondi, L.
Pinna, A. D.
Serra, C.
Golfieri, R.
Biasco, G.
Brandi, G.
机构：
[1] Univ Bologna, Bologna, Italy
[2] Azienda Osped Bologna, Policlin S Orsola Malpighi, Bologna, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e14608
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14608
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: Phase II study
    Lee, S
    Lee, E
    Jeong, H
    Lee, S
    Kim, J
    Shin, C
    Shim, J
    Kang, K
    Yoo, S
    In, K
    LUNG CANCER, 2005, 49 : S255 - S255
  • [22] CaboPoint: a Phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma
    Albiges, Laurence
    Schmidinger, Manuela
    Taguieva-Pioger, Naila
    Perol, David
    Grunwald, Viktor
    Guemas, Eric
    FUTURE ONCOLOGY, 2022, 18 (08) : 915 - 925
  • [23] The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation
    Matteo Ravaioli
    Alessandro Cucchetti
    Antonio Daniele Pinna
    Vanessa De Pace
    Flavia Neri
    Maria Aurelia Barbera
    Lorenzo Maroni
    Giorgio Frega
    Andrea Palloni
    Stefania De Lorenzo
    Maria Cristina Ripoli
    Maria Abbondanza Pantaleo
    Matteo Cescon
    Massimo Del Gaudio
    Giovanni Brandi
    Scientific Reports, 7
  • [24] Regorafenib promising second-line treatment in hepatocellular carcinoma
    不详
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2016, 77 (08) : 446 - 446
  • [25] Cabozantinib as a second-line treatment option in hepatocellular carcinoma
    D'Angelo, Alberto
    Sobhani, Navid
    Bagby, Stefan
    Casadei-Gardini, Andrea
    Roviello, Giandomenico
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2020, 13 (06) : 623 - 629
  • [26] METRONOMIC CAPECITABINE IN HEPATOCELLULAR CARCINOMA RELAPSE AFTER LIVER TRANSPLANTATION: A RETROSPECTIVE STUDY
    de Rosa, Francesco
    Agostini, Valentina
    Ravaioli, Matteo
    Cescon, Matteo
    Grazi, Gian Luca
    Di Girolamo, Stefania
    Nobili, Elisabetta
    Pinna, Antonio Daniele
    Biasco, Guido
    Brandi, Giovanni
    ANNALS OF ONCOLOGY, 2009, 20
  • [27] Advancements in second-line treatment research for hepatocellular carcinoma
    Sun, Ruirui
    Wu, Chenrui
    Gou, Yang
    Zhao, Yaowu
    Huang, Ping
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025, 27 (03): : 837 - 857
  • [28] How to Choose Second-Line Treatment for Hepatocellular Carcinoma
    Frenette, Catherine
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 726 - 729
  • [29] A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
    Lin, Zhong-Zhe
    Chen, Bang-Bin
    Hung, Yi-Ping
    Huang, Po-Hsiang
    Shen, Ying-Chun
    Shao, Yu-Yun
    Hsu, Chih-Hung
    Cheng, Ann-Lii
    Lee, Rheun-Chuan
    Chao, Yee
    Hsu, Chiun
    ONCOLOGIST, 2020, 25 (09): : E1280 - E1285
  • [30] Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer
    Borner, MM
    Dietrich, D
    Stupp, R
    Moran, R
    Honegger, H
    Wernli, M
    Herrmann, R
    Pestalozzi, BC
    Saletti, P
    Hanselmann, S
    Müller, S
    Brauchli, P
    Castiglione-Gertsch, M
    Goldhirsch, A
    Roth, AD
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) : 1759 - 1766
12345